Clinical Trial Update: Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating vorinostat in combination with bevacizumab for unresectable or metastatic renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Zolinza (vorinostat)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2015-09-09